CHAPTER 1. INTRODUCTION
1.1. Market Definition
1.2. Executive Summary
1.3. The Scope of the Study
CHAPTER 2. RESEARCH METHODOLOGY
2.1. Secondary Research
2.2. Primary Research
2.3. Analytic Tools and Model
2.4. Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5. Expert Validation
2.6. Study Timeline
CHAPTER 3. MARKET ANALYSIS
3.1. Industry Value Chain Analysis
3.2. Porter's Five Force Analysis
3.2.1. Bargaining Power of Buyers
3.2.2. Bargaining Power of Suppliers
3.2.3. Threats of Substitutes
3.2.4. Threats of New Entrants
3.2.5. Degree of Competition
3.3. PESTLE Analysis
3.3.1. Political
3.3.2. Economical
3.3.3. Social
3.3.4. Technological
3.3.5. Legal
3.3.6. Environmental
3.4. SWOT Analysis
3.4.1. Strengths
3.4.2. Weakness
3.4.3. Opportunities
3.4.4. Threats
3.5. Y-O-Y Analysis
CHAPTER 4. MARKET DYNAMICS
4.1. Market Drivers
4.1.1. Advantages over singleplex and traditional assays
4.1.2. Use of multiplex assays in companion diagnostics
4.1.3. Growing technological advancements in multiplex assays
4.1.4. The rapid development of nanoscience’s
4.2. Market Restraints & Challenges
4.2.1. Multiplex assays require considerable time and initial investment.
4.2.2. Stringent regulations and standards
4.3. Market Opportunities
4.3.1. Increasing validation of biomarkers in molecular and protein diagnostics
4.3.2. Need for high-throughput and automated systems
CHAPTER 5. GLOBAL MULTIPLEX ASSAYS MARKET – BY PRODUCT &
SERVICE
5.1. Consumables
5.2. Instruments
5.3. Software and Services
CHAPTER 6. GLOBAL MULTIPLEX ASSAYS MARKET – BY TYPE
6.1. Protein Multiplex Assays
6.1.1. Planar Protein Assays
6.1.2. Bead-Based Protein Assays
6.1.3. Other Protein Assays
6.2. Nucleic Acid Multiplex Assays
6.2.1. Planar Nucleic Acid Assays
6.2.2. Bead-Based Nucleic Acid Assays
6.2.3. Other Nucleic Acid Assays
6.3. Cell-Based Multiplex Assays
CHAPTER 7. GLOBAL MULTIPLEX ASSAYS MARKET – BY TECHNOLOGY
7.1. Flow Cytometry
7.2. Fluorescence Detection
7.3. Luminescence
7.4. Multiplex Real-Time PCR
7.5. Other Technologies
CHAPTER 8. GLOBAL MULTIPLEX ASSAYS MARKET – BY APPLICATION
8.1. Research & Development
8.1.1. Drug Discovery & Development
8.1.2. Biomarker Discovery & Validation
8.2. Clinical Diagnostics
8.2.1. Infectious Diseases
8.2.2. Cancer
8.2.3. Cardiovascular Diseases
8.2.4. Autoimmune Diseases
8.2.5. Nervous System Disorders
8.2.6. Metabolism & Endocrinology Disorders
8.2.7. Others
CHAPTER 9. GLOBAL MULTIPLEX ASSAYS MARKET – BY END USER
9.1. Pharmaceutical & Biotechnology Companies
9.2. Hospitals & Research Institutes
9.3. Reference Laboratories
9.4. Others
CHAPTER 10. GLOBAL MULTIPLEX ASSAYS MARKET - BY GEOGRAPHY
10.1. Introduction
10.2. North America
10.2.1. U.S.
10.2.2. Canada
10.2.3. Mexico
10.2.4. Costa Rica
10.3. South America
10.3.1. Brazil
10.3.2. Argentina
10.3.3. Chile
10.3.4. Columbia
10.3.5. Others
10.4. Europe
10.4.1. U.K.
10.4.2. Germany
10.4.3. France
10.4.4. Italy
10.4.5. Spain
10.4.6. Russia
10.4.7. Netherlands
10.4.8. Switzerland
10.4.9. Poland
10.4.10. Others
10.5. APAC
10.5.1. China
10.5.2. Japan
10.5.3. India
10.5.4. South Korea
10.5.5. Australia & New Zealand
10.5.6. Malaysia
10.5.7. Singapore
10.5.8. Others
10.6. Middle East & Africa
10.6.1. UAE
10.6.2. Saudi Arabia
10.6.3. Iran
10.6.4. Iraq
10.6.5. Qatar
10.6.6. South Africa
10.6.7. Algeria
10.6.8. Morocco
10.6.9. Nigeria
10.6.10. Egypt
10.6.11. Others
CHAPTER 11. GLOBAL MULTIPLEX ASSAYS MARKET - COMPANY PROFILES
11.1. Bio-Rad Laboratories, Inc.
11.2. Qiagen Bioinformatics
11.3. Abcam Bio-Technology Company
11.4. Becton Dickinson and Company
11.5. Merck & Company Inc.
11.6. Agilent Technologies
11.7. Meso Scale Diagnostics
11.8. Randox Laboratories
11.9. Quanterix Corporation
11.10. Bio-Techne Corporation
11.11. Olink AB
11.12. Seegene Inc.
11.13. Illumina, Inc.
11.14. Thermo Fisher Scientific
11.15. Luminex Corporation
CHAPTER 12. GLOBAL MULTIPLEX ASSAYS MARKET - COMPETITIVE
LANDSCAPE
12.1. Market Share Analysis
12.2. Strategies adopted by top companies
12.3. Mergers, Acquisitions, Collaborations & Agreements
CHAPTER 13. MARKET INSIGHTS
13.1. Industry Experts Insights
13.2. Analysts Opinions
13.3. Investment Opportunities
CHAPTER 14. APPENDIX
14.1. List of Tables
14.2. List of Figures
